Mainz Biomed N.V. (MYNZ) Stock Price, Quote & News

Company Profile

Mainz Biomed N.V. develops and sells in-vitro diagnostic (IVD) tests for the early detection of cancer in the United States and Europe. It offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. The company also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. In addition, it operates a clinical diagnostic laboratory; and distributes its IVD kits to third-party laboratories. The company has a collaboration agreement with Thermo Fishe...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 49 6131 554 2860

Website: mainzbiomed.com

Address:

Robert Koch Strasse 50, Mainz, Germany

Brokermax Jun. 16 at 9:28 PM

$MYNZ here we go ☝️

0 · Reply

Brokermax Jun. 16 at 9:01 PM

$MYNZ Im more in #ipa but #mynz should akso be interesting

0 · Reply

Brokermax Jun. 16 at 8:55 PM

$MYNZ ?

0 · Reply

Destructor Jun. 16 at 8:20 PM

$MYNZ Guido Bächler you dirty boy

0 · Reply

peterb030 Jun. 16 at 7:48 PM

$MYNZ you better stay away, far away....

1 · Reply

peterb030 Jun. 16 at 7:47 PM

$MYNZ part 2 the petra starke promise: • Validated by the eAArly DETECT study • Major alliances with Thermo Fisher and Quest Diagnostics • Expansion across Europe and the Middle East This isn’t just biotech progress. This is monumental. 🙏 We have a tool that can save lives. And we have a mission that cannot wait. Stay strong. Hold the line. Big things are coming. This is just the beginning—and I’m proud to be part of it. —Petra Starke Brand Ambassador, Mainz Biomed

0 · Reply

peterb030 Jun. 16 at 7:47 PM

$MYNZ from X, my friend: Vastgemaakt Petra Starke @StarkePetra · 3 apr. Great news is on the way from Mainz Biomed 🙏 🙏 🙏 Even tho so many generations have suffered from this disease 😢 help is on way 🙏 And I want to say this loud and clear: We finally have a chance to stop colorectal cancer before it starts. Colorectal cancer is on its way to becoming the #1 cancer killer of people under 50. That means no one is too young anymore—your children, your siblings, your friends. But there is hope. Real, tangible hope. And it’s being built by Mainz Biomed. With today’s financial results, we’re not just celebrating numbers—we’re declaring our mission: To end colorectal cancer through early detection. Here’s where we stand: • +33% year-over-year lab revenue growth — ColoAlert®️ is reaching more lives • 97% sensitivity detecting colorectal cancer • 100% detection of high-grade dysplasia • 82% detection of advanced precancerous lesions

0 · Reply

Brokermax Jun. 16 at 7:46 PM

$MYNZ Wow, what a bashing! Must be a hot stock 🔥☘️🔥

0 · Reply

peterb030 Jun. 16 at 7:37 PM

$MYNZ you wished that it was 1.99

0 · Reply

peterb030 Jun. 16 at 7:33 PM

$MYNZ holding overnight?

0 · Reply

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

May 19, 2025, 8:01 PM EDT - 4 weeks ago

Mainz Biomed Announces Pricing of $4.0 Million Follow-On Offering of Ordinary Shares and Warrants

May 16, 2025, 8:01 AM EDT - 4 weeks ago

Mainz Biomed Announces Interim Read Out For Its eAArly DETECT 2 Clinical Study

Apr 29, 2025, 8:01 AM EDT - 6 weeks ago

Mainz Biomed Enters into Technology Partnership with EDX Medical Group

Apr 28, 2025, 8:01 AM EDT - 7 weeks ago

Mainz Biomed Provides First Quarter 2025 Corporate Update and Path to FDA Premarket Approval

Mar 27, 2025, 9:01 AM EDT - 2 months ago

Mainz Biomed Enrolls First Patient in Its eAArly DETECT 2 Clinical Study

Mar 13, 2025, 8:01 AM EDT - 3 months ago

Mainz Biomed and Liquid Biosciences Make Groundbreaking Discovery of mRNA Biomarkers for Blood Based Detection of Pancreatic Cancer

Mar 3, 2025, 8:01 AM EST - 3 months ago

Colorectal Cancer Awareness Month: Mainz Biomed Advocates for a Shift from Screening to Prevention

Feb 20, 2025, 8:01 AM EST - 4 months ago

Mainz Biomed Expands into Switzerland with labor team w

Feb 11, 2025, 8:01 AM EST - 4 months ago

Mainz Biomed and GANZIMMUN Announce Launch of Enhanced ColoAlert Colorectal Cancer Screening Ahead of Awareness Month

Jan 27, 2025, 8:01 AM EST - 5 months ago

Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements

Jan 21, 2025, 8:01 AM EST - 5 months ago

Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population

Dec 19, 2024, 8:01 AM EST - 6 months ago

Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test

Dec 16, 2024, 5:00 PM EST - 6 months ago

Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering

Dec 12, 2024, 8:00 PM EST - 6 months ago

Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules

Dec 3, 2024, 2:40 PM EST - 6 months ago

Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific

TMO

Nov 29, 2024, 8:45 AM EST - 7 months ago

Mainz Biomed Announces Stock Split

Oct 21, 2024, 8:01 AM EDT - 8 months ago

Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update

Oct 8, 2024, 8:01 AM EDT - 8 months ago

Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version

Oct 1, 2024, 8:01 AM EDT - 9 months ago

Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025

Sep 18, 2024, 8:01 AM EDT - 9 months ago

Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador

Sep 4, 2024, 4:01 AM EDT - 10 months ago

Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert

Jul 25, 2024, 8:01 AM EDT - 11 months ago

Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience

Jul 9, 2024, 3:01 AM EDT - 1 year ago

Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test

Jul 2, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Provides Half Year 2024 Corporate Update

Jun 3, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024

May 31, 2024, 5:01 PM EDT - 1 year ago

Mainz Biomed Reports Results of 2024 Annual General Meeting

May 28, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting

May 20, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial

May 7, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.

Apr 25, 2024, 9:29 AM EDT - 1 year ago

Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic

Apr 9, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Reports Full Year 2023 Financial Results

Mar 19, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

Mar 18, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Mar 12, 2024, 8:01 AM EDT - 1 year ago

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Mar 5, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic

Feb 27, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community

Feb 22, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert®

Feb 21, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

Feb 6, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Establishes Physician-Led Laboratory Expanding Service Offering for Privately Insured Patients in Germany

Jan 11, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium

Jan 9, 2024, 8:01 AM EST - 1 year ago

Mainz Biomed Provides Year-End Corporate Review 2023

Dec 19, 2023, 3:39 PM EST - 1 year ago

Is This BioTech Play Severely Undervalued? BioTech Shares Promising Results From Colorectal Study

Dec 19, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees

Dec 12, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland

Dec 5, 2023, 9:01 AM EST - 1 year ago

Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers

Nov 29, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed's Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast

Nov 20, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 16, 2023, 8:01 AM EST - 1 year ago

Mainz Biomed Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 15, 2023, 9:01 AM EST - 1 year ago

Mainz Biomed Announces Closing of $5.0 million Registered Direct Offering

Brokermax Jun. 16 at 9:28 PM

$MYNZ here we go ☝️

0 · Reply

Brokermax Jun. 16 at 9:01 PM

$MYNZ Im more in #ipa but #mynz should akso be interesting

0 · Reply

Brokermax Jun. 16 at 8:55 PM

$MYNZ ?

0 · Reply

Destructor Jun. 16 at 8:20 PM

$MYNZ Guido Bächler you dirty boy

0 · Reply

peterb030 Jun. 16 at 7:48 PM

$MYNZ you better stay away, far away....

1 · Reply

peterb030 Jun. 16 at 7:47 PM

0 · Reply

peterb030 Jun. 16 at 7:47 PM

0 · Reply

Brokermax Jun. 16 at 7:46 PM

$MYNZ Wow, what a bashing! Must be a hot stock 🔥☘️🔥

0 · Reply

peterb030 Jun. 16 at 7:37 PM

$MYNZ you wished that it was 1.99

0 · Reply

peterb030 Jun. 16 at 7:33 PM

$MYNZ holding overnight?

0 · Reply

peterb030 Jun. 16 at 7:21 PM

0 · Reply

peterb030 Jun. 16 at 7:16 PM

$MYNZ before rs 0.04 cent

0 · Reply

peterb030 Jun. 16 at 7:15 PM

$MYNZ ever took the time to open their own website https://mainzbiomed.com/ front page breaking news 2024, funny germans....

0 · Reply

peterb030 Jun. 16 at 7:13 PM

$MYNZ if the german lose faith and call it bankrupt better sell: https://www.boersennews.de/community/diskussion/mainz-biomed/72286/

0 · Reply

peterb030 Jun. 16 at 7:12 PM

$MYNZ from the german forum : How do they manage to make sure that no one closes the doors? Where does the money come from? Who buys the newly issued shares? News of the week "Feasibility study to confirm old results"??? What's the point of all this? According to the latest SEC report, they only have half the board - on the website many more grin at me? Does the booth in Mainz still exist at all? Where are the Mainz people who used to be here? Can someone send a photo? Only open questions.

0 · Reply

peterb030 Jun. 16 at 7:10 PM

$MYNZ -10% 1.64

0 · Reply

peterb030 Jun. 16 at 7:09 PM

$MYNZ from german froum, sell before you lose everything: The stock is neither theoretically nor practically attractive. It is extremely cheapened by capital increases in order to fill the pockets of a bloated management, which the shareholder a.A. ignores. Every now and then, pushers like vultures come by with meaningless price targets. The supposedly great and unique diagnostics have long since been caught up with reality: grotesquely low sales for years, complete failure in recruiting for new study. The little money is burned for salaries, senseless contracts with half-silk product promoters and dubious laboratories in Hinterduckistan. The list of failures is long. Short target for 2026: €0.0, i.e. bankrupt.

0 · Reply

peterb030 Jun. 16 at 7:08 PM

$MYNZ from the german forun: And it should be said again: the stock was never at €1,000! This is the result of an endless series of reverse splits, starting half a year after the IPO, in which the shareholders have bled dry again and again until we have now reached 7.5 million dollars market capitalization. It borders on intent to have deliberately financed excessively dimensioned salaries and other bells and whistles with capital increases. The supervisory board has completely failed to rein in costs. Marketing has completely failed to market a good product. And management has failed to rely on FDA coverage and approval instead of relying on private health insurance in Europe and Germany

0 · Reply

peterb030 Jun. 16 at 7:07 PM

$MYNZ The fact that Mainz Biomed is listed on German stock exchanges so long after the resplit (almost 6 months!)still not tradable speaks volumes. Here, a company deliberately refuses to trade transparency. But the fact that the small shareholder MB am A... is also nothing really new. However, the behavior is increasingly taking on criminal traits.

0 · Reply

peterb030 Jun. 16 at 7:02 PM

$MYNZ everybody warned you, the forum was even closed, 300 real people here and 30k bots paid to fool people like you, you better buy $HOLO or $MLGO 1.50 close? or will they keep it here around 1.70 with small buys out the bid

0 · Reply

Chaine Jun. 16 at 5:43 PM

$MYNZ What the heck is happening here? Why was it at $8.00 and more 5 months ago? I am really scared now… losing 81% on more than $56K

0 · Reply

STARKTWITZ Jun. 16 at 4:33 PM

$MYNZ

0 · Reply

Market Cap	6.30M
Revenue (ttm)	890,000.00
Net Income (ttm)	-21.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-2,432.58%
Debt to Equity Ratio	0.18

Volume	121,100
Avg Vol	173,556
Day's Range	N/A - N/A
Shares Out	3.44M
Stochastic %K	4%
Beta	0.30
Analysts	Sell
Price Target	$14.00